Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Biogen licenses Karyopharm treatment
by Ryan Cross
February 5, 2018
| A version of this story appeared in
Volume 96, Issue 6
Biogen kicked off the year with a small deal to acquire a compound from Karyopharm Therapeutics that could potentially treat amyotrophic lateral sclerosis, traumatic brain injury, and other inflammatory conditions. Biogen will pay $10 million up front for the compound, called KPT-350, and up to $207 million in milestone payments. KPT-350 is an orally available molecule that is able to enter the brain and block a nuclear transport receptor. Blocking this receptor helps retain anti-inflammatory proteins within the nucleus of a cell. Karyopharm is developing similar molecules for cancer treatments.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter